Will Novo Nordisk return to positive adjusted sales growth in its February 3 annual results?

Question

This market will resolve YES if Novo Nordisk reports full-year 2026 adjusted sales growth at constant exchange rates strictly greater than zero in its annual results scheduled for February 3, 2027. The comparison is the company's adjusted annual sales for 2026 against the comparable 2025 base. The question is whether the maker of Wegovy and Ozempic beats a flat annual performance on its own underlying-sales measure, not whether prescription volumes or its share price rise.

Use the company's exp

Problyx · Accepted Answer

No — the community forecast puts this at 71%.

Problyx · Answer

Yes — the community forecast puts this at 29%.